Oncofusion

start / graph / cell-type-car-cell

Cell typestrong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.Q-marrow-niche

CAR cell (CXCL12-abundant reticular) / LEPR+ perivascular stromal cell — the cell that makes the signal holding blood stem cells in the marrow

also called CXCL12-abundant reticular cell · CAR cell · LEPR+ perivascular stromal cell · Prx1+ mesenchymal cell (overlapping population) · adipo-osteogenic progenitor

These are branching support cells wrapped around the blood vessels of the bone marrow, and they produce most of the chemical beacon (CXCL12) that keeps blood stem cells from drifting away. In leukaemia they are the cells that feed and shelter the cancer's own stem cells.

The same thing, for a scientist

CXCL12-abundant reticular (CAR) cells were defined by CXCL12 reporter intensity as the stromal cells most HSCs are in contact with, surrounding sinusoidal endothelium or lying near the endosteum; induced CXCR4 deletion in adults collapses the HSC pool, establishing the axis they serve [E1]. Conditional-deletion work subsequently localised the essential maintenance factors to **leptin-receptor (LEPR)-expressing perivascular stromal cells and endothelium**, and the field now treats CAR and LEPR+ cells as largely the same population identified by two markers [E2]. The KMT2A-relevant result is specific and recent: in an MLL::AF9 AML model, **CXCL12 produced by Prx1-positive mesenchymal cells, but not by mature osteolineage cells, maintains leukaemia stem cells**, and it does so by controlling energy metabolism and redox balance — Cxcl12 deletion caused ROS accumulation and DNA damage in LSCs and impaired their ability to perpetuate leukaemia on transplantation, a defect **attenuated by antioxidant therapy**, with evidence the phenomenon is conserved in human patients [E3]. So the cell that shelters the leukaemic stem cell is a mesenchymal perivascular cell, and the shelter it provides is metabolic.

Go deeper
What the cell is

A reticular cell is a stellate, branching stromal cell that forms a mesh through a tissue. CAR cells are the marrow's reticular cells that express CXCL12 at very high level. Sugiyama and colleagues found that most HSCs are in physical contact with one, and that these cells sit both around sinusoids and near the endosteum — meaning that a single stromal population spans the two anatomical compartments the field had been treating as rival niches 1.

They are not a terminal cell type. CAR/LEPR+ cells are adipo-osteogenic progenitors: they are the source of marrow adipocytes and of osteoblasts, which links this entry to cell-type-bone-marrow-adipocyte and cell-type-osteoblast as differentiated descendants rather than as unrelated neighbours.

Naming caution. The literature calls overlapping versions of this population CAR cells, LEPR+ cells, Prx1+ (Prrx1) mesenchymal cells, and in some papers simply MSC. These labels are reporter alleles, not proofs of identity, and this entry does not assert that they mark exactly the same cells. Where a specific result is cited, the marker actually used is stated.

The leukaemia result, and why it is not the protection story you would expect

The CXCL12/CXCR4 axis is routinely invoked as the pathway by which stroma shelters leukaemic cells from chemotherapy. Viñado and colleagues asked where the CXCL12 comes from and what it actually does, in an MLL::AF9 model. Their answer: Prx1+ mesenchymal cells, not mature osteolineage cells, and the protection is metabolic rather than simply anti-apoptotic — deleting Cxcl12 caused reactive oxygen species to accumulate and DNA damage to appear in leukaemia stem cells, impairing serial transplantation, and antioxidant therapy attenuated the defect 3.

That last clause is the interesting one, and it cuts against the simple reading. If the niche's contribution can be replaced by an antioxidant, then what the niche supplies is a metabolic buffer, not an inviolable sanctuary. It also means that a CXCR4 antagonist given with an antioxidant would be expected to work less well, which is a concrete, testable and clinically relevant prediction that nobody appears to have tested.

Separately, a CRISPR screen in the same MLL-AF9 background found CXCR4 essential to the leukaemia independently of CXCL12: Cxcr4 deletion eradicated leukaemia without impairing marrow homing, and CXCL12 was dispensable for leukaemia development in recipients 4. Read together, 3 and 4 say that the ligand matters (from Prx1+ cells) and that the receptor's essentiality does not require the ligand. The field has not reconciled these, and an entry that reported only one of them would misrepresent the state of knowledge.

Facts and figures
ontologyCL:0002092 (bone marrow cell); no dedicated CL term for CAR cell as of this writing
locationperivascular, surrounding sinusoidal endothelium and extending to endosteal regions
markers
[
  "CXCL12 high",
  "LEPR",
  "PDGFRA/PDGFRB",
  "Prx1 (Prrx1) lineage",
  "CD45 negative, Ter119 negative"
]
secreted factors
[
  "CXCL12 (SDF-1)",
  "SCF (KITL)",
  "IL-7"
]
differentiation potential
[
  "adipocyte",
  "osteoblast"
]
kmt2a relevance
{
  "finding": "Prx1+ mesenchymal CXCL12, not mature osteolineage CXCL12, maintains MLL::AF9 leukaemia stem cells via energy metabolism and redox balance",
  "unexpected_detail": "antioxidant therapy attenuates the defect caused by Cxcl12 deletion, implying the niche supplies a replaceable metabolic buffer rather than an inviolable sanctuary",
  "conflict": "a CRISPR screen in the same driver reports CXCR4 essential but CXCL12 dispensable"
}
atlas refs
[
  {
    "label": "CAR cells and CXCL12-CXCR4 maintenance of the HSC pool",
    "pmid": "17174120",
    "title": "Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches.",
    "authors": "Sugiyama T, Kohara H, Noda M, et al.",
    "venue": "Immunity",
    "year": 2006,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "label": "Prx1+ mesenchymal CXCL12 maintains MLL::AF9 LSCs via redox balance",
    "pmid": "35618797",
    "title": "The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells.",
    "authors": "Viñado AC, Calvo IA, Cenzano I, et al.",
    "venue": "Leukemia",
    "year": 2022,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  }
]
How this could bite us back
  • CXCL12 from this cell maintains normal HSCs as well as leukaemic ones, so blocking the axis mobilises the patient's remaining healthy stem cells at the same time — which is exactly how plerixafor is used deliberately in donors.
  • If antioxidants substitute for the niche's metabolic support, then supportive care that raises antioxidant capacity could unintentionally rescue leukaemic stem cells from a niche-disrupting drug.
  • The receptor may be essential for a reason the ligand is not involved in, so a ligand-blocking strategy and a receptor-blocking strategy are not interchangeable even though the field treats them as such.
Still open
  1. Does a CXCR4 antagonist lose efficacy when given with an antioxidant? [E3] implies it should, and that would be a decisive test of whether the niche's contribution to KMT2A-rearranged LSC survival is metabolic.
  2. Are the CAR, LEPR+, Prx1+ and Nestin+ labels marking one population or several? Every functional claim in this entry depends on an answer nobody has supplied.
  3. Has anyone identified the human paediatric equivalent of a CAR cell in a diagnostic marrow trephine, and does its abundance at diagnosis predict measurable residual disease?
  4. Does KMT2A::AFF1 infant ALL depend on Prx1+ mesenchymal CXCL12 as MLL::AF9 AML does? The stromal-protection data in infant ALL are real but the cellular source of the protective signal was never identified.
Every source behind this entry (4)
  1. E1established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.paper

    Most HSCs are in contact with CXCL12-abundant reticular (CAR) cells, which surround sinusoidal endothelial cells or lie near the endosteum; induced deletion of CXCR4 in adult mice severely reduces HSC numbers and increases sensitivity to myelotoxic injury without impairing expansion of more mature progenitors, establishing CXCL12-CXCR4 signalling as essential for maintaining the quiescent HSC pool.

    PMID 17174120DOI
    What this evidence cannot show

    Mouse. CAR identity rests on a CXCL12 reporter, so the population is defined by the molecule whose importance is being demonstrated. The HSC-contact claim is a static histological association. Read: abstract only.

    Evidence that argues against this (1)
    • Conditional deletion of the other key maintenance factor, SCF, showed the requirement lies with LEPR-expressing perivascular cells and endothelium, and that deletion from osteoblasts or Nestin-cre cells was dispensable. This does not refute the CAR result but it relocates the functional definition of the niche cell from a CXCL12 reporter to a LEPR-driven cre, and the two populations are assumed rather than shown to be identical. Read: abstract only. Ding L et al. 2012
  2. E2established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.paper

    SCF is expressed primarily by perivascular cells throughout bone marrow; HSCs are depleted when Scf is conditionally deleted from endothelial cells or from leptin-receptor-expressing perivascular stromal cells, and most HSCs are lost when deleted from both, whereas deletion from haematopoietic cells, osteoblasts or Nestin-cre-expressing cells has no effect.

    Endothelial and perivascular cells maintain haematopoietic stem cells · Ding L, Saunders TL, Enikolopov G, Morrison SJ · Nature 2012
    PMID 22281595DOI
    What this evidence cannot show

    Mouse conditional genetics. Cre-driver specificity is the central methodological weakness of this whole literature and is the explicit basis on which the Nestin group disputes the negative Nestin-cre result. Read: abstract only.

    Evidence that argues against this (1)
    • Nestin-GFP-positive MSCs were independently shown to contain all marrow CFU-F activity, to express HSC-maintenance genes highly, and to be required for marrow HSC content and progenitor homing when depleted in vivo. If Nestin+ cells are dispensable as an SCF source but required as a population, then SCF production is not the whole of what the perivascular niche cell does. Read: abstract only. Mendez-Ferrer S et al. 2010
  3. E3strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper

    In an MLL::AF9-induced AML model, CXCL12 produced by Prx1-positive mesenchymal cells but not by mature osteolineage cells maintains leukaemia stem cells in the marrow by modulating energy metabolism and redox balance; Cxcl12 deletion causes reactive oxygen species accumulation and DNA damage in LSCs and impairs their ability to perpetuate leukaemia in transplantation, a defect attenuated by antioxidant therapy, with data suggesting the phenomenon is conserved in human patients.

    The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells · Vinado AC, Calvo IA, Cenzano I, Olaverri D, Cocera M, San Martin-Uriz P, et al. · Leukemia 2022
    PMID 35618797DOI
    What this evidence cannot show

    Mouse MLL::AF9. Prx1-cre is a broad limb-bud mesenchymal driver that recombines in much of the skeletal mesenchyme, so 'Prx1+ mesenchymal cells' is a compartment rather than a defined cell type. The human conservation claim is described in the abstract as suggestive. Read: abstract only.

    Evidence that argues against this (1)
    • A CRISPR screen in a syngeneic MLL-AF9 model found CXCR4 essential for AML in vivo but CXCL12 DISPENSABLE for leukaemia development in recipient mice, and Cxcr4 deletion eradicated leukaemia without impairing homing to marrow. If the ligand is dispensable in that system, the niche-derived CXCL12 requirement is either model-dependent or is doing something other than engaging CXCR4 on the leukaemic cell. Read: abstract only. Ramakrishnan R et al. 2020
  4. E4strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper

    A CRISPR-Cas9 cell-surface screen in a syngeneic MLL-AF9 mouse AML model identified CXCR4 as a top regulator of AML cell growth and survival; Cxcr4 deletion eradicated leukaemia cells in vivo without impairing their homing to bone marrow, CXCL12 was dispensable for leukaemia development in recipients, mutant CXCR4 variants showed signalling is required, and loss of CXCR4 signalling caused oxidative stress and differentiation in vivo.

    CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia · Ramakrishnan R, Pena-Martinez P, Agarwal P, Rodriguez-Zabala M, Chapellier M, Hogberg C, et al. · Cell Reports 2020
    PMID 32460032DOI
    What this evidence cannot show

    Mouse syngeneic MLL-AF9; 'CXCL12 dispensable' rests on the recipient genotype, which does not exclude leukaemia-cell-autonomous or alternative-ligand stimulation. The result is myeloid and does not address KMT2A-rearranged ALL, where the human niche-protection data actually sit. Read: abstract only.

    Evidence that argues against this (1)
    • The KMT2A-rearranged human data point the other way on the ligand's relevance: primary infant MLL-rearranged ALL is differentially protected by stroma, stroma-conditioned medium alone is sufficient, and CXCR4 antagonism with AMD3100 markedly enhanced drug efficacy in xenografts. A CXCL12-independent mechanism in murine myeloid disease does not transfer to that setting. Read: abstract only. Sison EA et al. 2013
Connected to